Access Dermatology

Breaking News

• Breaking News List »
• 2009 »
• April »

Rapid improvement in quality of life with etanercept therapy in psoriasis with psoriatic arthritis

A 12-week, double-blind, multicenter trial with a 12-week open-label extension (OLE) phase enrolled 751 patients with moderate-severe plaque psoriasis and psoriatic arthritis (PsA) to evaluate quality of life following two etanercept regimens. The regimens were etanercept 50 mg biweekly (n = 379) or etanercept 50 mg/week (n = 372) for 12 weeks followed by an OLE of etanercept 50 mg/week for 12 weeks. The EuroQoL 5D (EQ-5D) was measured at baseline and subsequent visits. The Dermatology Life Quality Index (DLQI) and Health Assessment Questionnaire (HAQ) were also assessed. The mean baseline EQ-5D scores were 0.48 and 0.49 for etanercept 50 mg biweekly and etanercept 50 mg/week, respectively. At week 3 these ...